15% earnings surge gets CSL's blood pumping
15% earnings surge gets CSL's blood pumping
About this video
Key points:
CSL (ASX:CSL) seen as a 5% growth, market‑multiple stock with unresolved margin questions
Cochlear (ASX:COH) viewed as a fallen growth star, now driven by cost reductions and modest earnings guidance
BHP (ASX:BHP) positioned as a copper‑focused miner with solid dividends but cyclical risk
David Walsh from Sarto Advisory sets out a cautious stance on Australia’s healthcare heavyweights and mining giant BHP, highlighting valuation risks and slower growth expectations.,Walsh describes CSL (ASX:CSL) as delivering an “in‑line” result with no downgrade for the first time in four periods, which he expects to be received positively in the short term. However, he sees limited evidence of margin improvement in CSL Behring’s albumin and IG businesses and characterises CSL as a 5% growth story deserving roughly a market multiple. He would not buy at current levels, despite holding the stock, citing uncertainty over future growth drivers and leadership in key divisions.
On Cochlear (ASX:COH), Walsh notes repeated downgrades and a subsequent share price battering, but now sees a modest turnaround with guidance at the top end and a 3–5% earnings growth outlook. He argues both CSL and Cochlear have shifted from high-growth franchises to “cost‑out” stories, still trading at premium valuations.
Turning to BHP (ASX:BHP), Walsh points to copper now generating over half of EBITDA following the Oz Minerals acquisition. He views the result and dividend as strong, with a broadly positive outlook tempered by concerns over China, higher energy costs and shipping disruptions, while stressing the cyclical nature of commodities.,